Search
for
Sort by
Research 30 of 77
- Skin bacteriota ameliorates androgenetic alopecia via harmonizing skin immuno inflammatory balance
- Cellular senescence and polycystic ovary syndrome: mechanisms and therapeutic strategies from a new perspective
- Advances in the mechanism and new therapies of alopecia areata
- Serum Interleukin 17 in Patients with Pattern Hair Loss
- Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02
- Frontal Fibrosing Alopecia
- Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies—A Narrative Review
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Updated Management of Atrophic Post Acne Scars: Review Article
- Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Interrelation of immunity and tissue repair or regeneration
- Social Status May Interfere in the Prognosis of Frontal Fibrosing Alopecia in Female Patients: An Observational Study
- Кореляційний аналіз взаємозв’язку хронічних дерматозів із соматичною патологією та обґрунтування детоксикаційної терапії
- Alopecia areata & periodontal diseases- A connecting link: A review
- Effect of decellularisation methods on methacryloyl-substituted placental ECM hydrogels
- Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*
- Safety and Biocompatibility of Mupirocin Nanoparticle-Loaded Hydrogel on Burn Wound in Rat Model
- Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
- Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Perceived Stigma and Mental Health Disorders Among Adults With Alopecia Areata Living in Japan
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: A descriptive study using Japan medical data center claims database